AstraZeneca reports Phase III data

AstraZeneca (AZN; LSE:AZN) reported data from three Phase III trials showing that its Crestor rosuvastatin HMG-CoA reductase inhibitor reduced LDL cholesterol by 40%-58%. In a 516-patient study, Crest...